NEW YORK (GenomeWeb News) – Agilent Technologies and Covaris have struck a co-marketing agreement for their target enrichment and DNA shearing technologies for next-generation sequencing studies, Agilent said today.

Under the agreement, the Covaris S2 DNA shearing technology will be marketed with Agilent's SureSelect Target Enrichment System to researchers using next-generation sequencing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.